How long can patients with multiple myeloma live?

Multiple myeloma, as a malignant tumor originating from bone marrow plasma cells, is a type of plasma cell disease in the blood system. It is highly malignant and mostly has a poor prognosis. However, with the continuous advancement of medical technology and the continuous emergence of new drugs, the survival period of patients with multiple myeloma has been significantly improved.

As for the survival time of patients with multiple myeloma, this is a relatively complex issue because it is affected by many factors, including the patient's own condition, treatment methods, and disease stage. Generally speaking, if patients do not take treatment measures, the survival period may be only6-12 months. After traditional chemotherapy, the median survival time can be extended to 2-3 years. With the emergence of new drugs such as immunomodulators, proteasome inhibitors, monoclonal antibodies, etc., combined with autologous stem cell transplantation, most patients can achieve deep remission and survive for more than 5 years. For younger patients with suitable donors, allogeneic hematopoietic stem cell transplantation may even achieve clinical cure.

It is worth noting that there are large individual differences in the survival time of patients with multiple myeloma. With active treatment and effective management, some patients can survive for more than 10 years. However, some patients may have a relatively short survival period due to severe disease, poor response to treatment, or other complications.

In addition, the survival time of multiple myeloma is also related to the patient's age, health status, diagnosis time, treatment response and other factors. Younger patients are generally more tolerant to treatment and have easier dose adjustments, and therefore have relatively higher survival rates. At the same time, early diagnosis and early treatment are also the keys to improving survival rates.

In general, although multiple myeloma is still an incurable disease, the survival period of patients has been significantly extended through active treatment and effective management. Therefore, for patients with diagnosed multiple myeloma, it is important to actively cooperate with the doctor's treatment recommendations and maintain a good mentality and lifestyle to improve survival rate and quality of life.

(Common multiple myeloma treatment drugs include: melphalan, melphalan, bortezomib, ixazomib, etc. For specific drug details, please see the website homepage or click for consultation.)